H1 2017, Celiac Disease (Gastrointestinal) Pipeline Market Landscape Review Report
Celiac Disease Pipeline Market Review, H1 2017 report provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).This report find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).
Pune, India – April 25, 2017 /MarketersMedia/ —
ReportsnReports.com latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease – Pipeline Review, H1 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.
Browse 35 Tables and Figures, 13 Company Profiles, spread across 82 pages available @ http://www.reportsnreports.com/contacts/discount.aspx?name=958314.
Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogrens syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.
Celiac Disease – Companies Involved in Therapeutics Development
Amgen Inc, Amyra Biotech AG, Calypso Biotech SA, Circle33 LLC, enGene Inc, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, ImmusanT Inc, Innovate Biopharmaceuticals Inc, Intrexon Corp, Sanofi, Takeda Pharmaceutical Company Ltd, Zedira GmbH
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Celiac Disease – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Order a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=958314.
Scope of the report:
– The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)
List of Tables
Number of Products under Development for Celiac Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Celiac Disease – Pipeline by Amgen Inc, H1 2017
Celiac Disease – Pipeline by Amyra Biotech AG, H1 2017
Celiac Disease – Pipeline by Calypso Biotech SA, H1 2017
Celiac Disease – Pipeline by Circle33 LLC, H1 2017
Celiac Disease – Pipeline by enGene Inc, H1 2017
About Us
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
Contact Info:
Name: Ritesh Tiwari
Email: sales@reportsandreports.com
Organization: ReportsnReports.com
Address: Magarpatta City, Pune, Maharashtra, India
Phone: +1-888-391-5441
For more information, please visit http://www.reportsnreports.com/reports/958314-celiac-disease-pipeline-review-h1-2017.html
Source: MarketersMedia
Release ID: 189602
Copyright © 1999-2013 SproutNews.com
